Neutralizing shapeshifting pericytes enhances glioblastoma therapeutic efficacy
Maraviroc,an FDA-approved therapy,provides a potentially viable treatment option for those diagnosed with glioblas-toma harboring a high amount of pericyte support cells.
Glioblastoma (GBM) is the most common primary malignant brain tumor,and prognosis remains poor,with a median survival of < 16-20 months1.Conventional therapeutic interventions for GBM,including radiation and non-specific chemotherapeutic treatments,are designed to target tumor cells and their intrinsic signaling programs rather than to influence various cell types in the surrounding microenvironment.Refocusing the intended target of therapeutic strategies to cell-extrinsic mechanisms in the surrounding tumor microenvironment and the molecular interactions between GBM cells and surrounding cells has provided a crucial framework for novel treatment strategies and future discoveries2.
31
2021-11-11(万方平台首次上网日期,不代表论文的发表时间)
共2页
1039-1040